{{medical}}{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477172778
| drug_name =
| IUPAC_name = (7''S'',9''E'',11''S'',12''R'',13''S'',14''R'',15''R'',16''R'',17''S'',18''S'',19''E'',21''Z'')-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-{(''E'')-[(4-methylpiperazin-1-yl)imino]methyl}-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1<sup>4,7</sup>.0<sup>5,28</sup>]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate
| image = Rifampicin structure.svg
| width = 275
| image2 = Rifampicin 3D 1i6v.png
| width2 = 225

<!--Clinical data-->
| pronounce   = {{IPAc-en|r|ɪ|ˈ|f|æ|m|p|ə|s|ɪ|n}}
| tradename = Rifadin
| Drugs.com = {{drugs.com|monograph|rifampin}}
| MedlinePlus = a682403
| licence_US = Rifampin
| pregnancy_AU = C
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 口服、[[靜脈注射|靜脈注射]]

<!--Pharmacokinetic data-->
| bioavailability = 90－95%（口服）
| protein_bound = 80%
| metabolism = [[肝脏|肝脏]]及肠壁
| elimination_half-life = 3–4 小時
| excretion = 尿液（－30%）、糞便（60–65%）

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 13292-46-1
| ATC_prefix = J04
| ATC_suffix = AB02
| ATC_supplemental = {{ATCvet|J54|AB02}}
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 28077
| PubChem = 5381226
| IUPHAR_ligand = 2765
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB01045
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10468813
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = VJT6J7R4TR
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00211
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 374478
| NIAID_ChemDB = 007228
| PDB_ligand = RFP

<!--Chemical data-->
| C=43 | H=58 | N=4 | O=12
| molecular_weight = 822.94 g/mol
| smiles = CN1CCN(CC1)/N=C/c2c(O)c3c5C(=O)[C@@]4(C)O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(\C)C(=O)Nc2c(O)c3c(O)c(C)c5O4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JQXXHWHPUNPDRT-WLSIYKJHSA-N
| synonyms =
| melting_point = 183
| melting_high = 188
| boiling_point = 1004.42
| boiling_notes = <ref>{{cite web|title=Rifampicin (CAS 13292-46-1)|url=http://www.scbt.com/datasheet-200910-rifampicin.html|website=Santa Cruz Biotechnology Product Block|publisher=Santa Cruz Biotechnology|accessdate=14 November 2014|ref=http://www.scbt.com/datasheet-200910-rifampicin.html}}</ref>
}}

<!-- Definition and medical uses -->
'''利福平'''（{{lang|en|Rifampicin}}）為一種廣效性[[抗細菌藥|抗生素]]<ref name=AHFS2015>{{cite web|title=Rifampin
|url=http://www.drugs.com/monograph/rifampin.html|publisher=The American Society of Health-System Pharmacists|accessdate=Aug 1, 2015}}</ref>，可治療包含[[結核|結核病]]、[[痲瘋病|痲瘋病]]，以及[[軍團病|軍團病]]等疾病<!-- <ref name=AHFS2015 /> -->。利福平通常與其他抗生素合用，除了用於預防B型[[流感嗜血桿菌|流感嗜血桿菌]]以及{{tsl|en|meningococcal disease||腦膜炎球菌}}<!-- <ref name=AHFS2015 /> -->。如果要長期用藥，建議監測血球數量及肝臟酵素功能<!-- <ref name=AHFS2015 /> -->。本品为红色或暗红色的结晶状粉末，不溶于水，可透過口服及靜脈注射給藥<ref name=AHFS2015 />。

<!-- Side effects and mechanism-->
常見副作用包含惡心、嘔吐、腹瀉，以及食慾降低<!-- <ref name=AHFS2015 /> -->。尿液、汗液及淚液成紅色或橙色屬正常現象<!-- <ref name=AHFS2015 /> -->，另可能會造成肝臟傷害及過敏反應<!-- <ref name=AHFS2015 /> -->。本品常用於治療罹患開放性肺結核的孕婦，但其對於胎兒的傷害尚未明瞭<!-- <ref name=AHFS2015 /> -->。利福平屬於{{tsl|en|rifamycin|利福黴素}}<!-- <ref name=AHFS2015 /> -->，其作用機轉為阻斷細菌的[[核糖核酸|RNA]]轉錄<ref name=AHFS2015 />。

<!-- History, society and culture -->
利福平於1957年首次合成，並於1971年上市<ref name=Ox2009>{{cite book|title=Oxford Handbook of Infectious Diseases and Microbiology|date=2009|publisher=OUP Oxford|isbn=978-0-19-103962-1|page=56|url=https://books.google.ca/books?id=5W-WBQAAQBAJ&pg=PT56}}</ref><ref name=Mc2011 />。本品列名於[[世界卫生组织基本药物标准清单|世界卫生组织基本药物标准清单]]，為基礎公衛體系必備藥物之一<ref>{{cite web|url=http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf|title=19th WHO Model List of Essential Medicines (April 2015)|date=April 2015|accessdate=May 10, 2015|publisher=WHO}}</ref>。利福平屬於[[學名藥|學名藥]]<ref name=AHFS2015 />，在[[發展中國家|發展中國家]]一個月療程所需藥物的批發價約為3.90美金<ref>{{cite web|title=Rifampicin|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=RIF600T&s_year=2014&year=2014&str=600%20mg&desc=Rifampicin&pack=new&frm=TAB-CAP&rte=PO&class_code2=06%2E2%2E4%2E&supplement=&class_name=%2806%2E2%2E3%2E%29Antileprosy%20medicines%3Cbr%3E%2806%2E2%2E4%2E%29Antituberculosis%20medicines%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=24 August 2015}}{{dead link|date=2018年5月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>。在美國境內，同樣的劑量則需 120 美金<ref name=AHFS2015 /><ref>{{cite book|last1=Hamilton|first1=Richard J.|title=Tarascon pocket pharmacopoeia: 2014 deluxe lab-pocket edition|date=2014|publisher=Jones & Bartlett Learning|location=Sudbury|isbn=978-1-284-05399-9|page=39|edition=15|url=https://books.google.ca/books?id=BwqEAgAAQBAJ&pg=PA39}}</ref>。利福平是由''{{tsl|en|Amycolatopsis rifamycinica||Amycolatopsis rifamycinica}}''中提煉而得<ref name=Mc2011>{{cite book|last1=McHugh|first1=Timothy D.|title=Tuberculosis: diagnosis and treatment|date=2011|publisher=CABI|location=Wallingford, Oxfordshire|isbn=978-1-84593-807-9|page=219|url=https://books.google.ca/books?id=YAGnWQUsCKcC&pg=PA219}}</ref>。

==毒副作用==
利福平口服[[毒性|毒性]]小，偶尔使[[消化道|消化道]]产生不良反应，有腹胀、食欲减退等。因为药物代谢会在肠道反复代谢，会出现尿液等体液橘红色现象，一般停用后即可恢复。少数病人出现[[黄疸|黄疸]]、[[血清转氨酶|血清转氨酶]]升高，与异烟肼合用发生率增高。并可能引起[[肝功能|肝功能]]损害。

==作用机理==
利福平的作用机制是抑制病原体DNA的RNA多聚酶，抑制病原体RNA合成的起始阶段，抑制细菌RNA的合成从而阻止细菌DNA和蛋白的合成。

== 參考文獻 ==
{{reflist|2}}

== 外部連結 ==
* [https://web.archive.org/web/20081208024312/http://www.pubpk.org/index.php?title=Rifampicin PubPK – Rifampicin pharmacokinetics]
* [http://products.sanofi-aventis.us/rifadin/Rifadin.pdf Prescribing Information for RIFADIN by Sanofi-Aventis]
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Rifampicin U.S. National Library of Medicine: Drug Information Portal – Rifampicin]
* [https://archive.is/20130222050947/http://www.pdr.net/drugpages/concisemonograph.aspx?concise=564 PDR.net Concise Monograph – Rifadin]

{{Antimycobacterials}}
{{Nucleic acid inhibitors}}
{{DNA antivirals}}
{{PXR ligands}}

{{tsl|en|Category:Pregnane X receptor agonists||Category:Pregnane X receptor agonists}}

[[Category:麻风|Category:麻风]]
[[Category:哌嗪|Category:哌嗪]]
[[Category:利福霉素抗生素|Category:利福霉素抗生素]]
[[Category:结核病|Category:结核病]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]